SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Revenue showed a marginal decline at Rs. 247.02 millions. For the quarter ended September 2021, as compared to corresponding quarter of last year.The Net Loss for the quarter ended September 2021 is Rs. -93.60 millions as compared to Net Loss of Rs. -38.66 millions of corresponding quarter ended September 2020 Operating profit Margin for the quarter ended September 2021 improved to -32.74% as compared to -43.60% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 247.02 253.58 -2.59 389.17 445.11 -12.57 853.34 668.37 27.67
Other Income 2.17 1.38 57.25 4.66 -4.44 -204.95 98.32 11.84 730.41
PBIDT -32.74 -43.60 -24.91 -19.85 -43.14 -53.99 -122.28 -92.25 32.55
Interest 12.28 11.66 5.32 23.84 22.57 5.63 47.70 47.42 0.59
PBDT -45.02 -55.26 -18.53 -43.69 -65.71 -33.51 -169.98 -139.67 21.70
Depreciation 0.57 0.59 -3.39 1.16 1.18 -1.69 2.37 2.37 0.00
PBT -45.59 -55.85 -18.37 -44.85 -66.89 -32.95 -172.35 -142.04 21.34
TAX 48.01 -17.19 -379.29 29.48 -20.38 -244.65 -41.55 -39.92 4.08
Deferred Tax 48.01 -17.19 -379.29 29.48 -20.38 -244.65 -41.55 -39.92 4.08
PAT -93.60 -38.66 142.11 -74.33 -46.51 59.82 -130.80 -102.12 28.08
Equity 431.80 431.80 0.00 431.80 431.80 0.00 431.80 431.80 0.00
PBIDTM(%) -13.25 -17.19 -22.91 -5.10 -9.69 -47.37 -14.33 -13.80 3.82

Bharat Immunological Share Price

17.20 0.34 (2.02%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×